Retinal detachment

Adjunctive intravitreal drug therapy

Evidence for the prevention of postoperative proliferative vitreoretinopathy (a cause of failure of retinal reattachment surgery) with low-molecular-weight heparin alone, or with fluorouracil, is inconsistent.[60]Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD006421. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006421.pub3/full http://www.ncbi.nlm.nih.gov/pubmed/23440808?tool=bestpractice.com ​ One randomized, double-blind trial to evaluate the preventive effect of intravitreal fluorouracil and heparin in high-risk patients with retinal detachment is ongoing.[61]Schaub F, Hoerster R, Schiller P, et al. Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial. Trials. 2018 Jul 16;19(1):384. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048849 http://www.ncbi.nlm.nih.gov/pubmed/30012187?tool=bestpractice.com [62]US National Library of Medicine. ​Prophylactic intravitreal 5-fluorouracil and heparin to prevent PVR in high-risk patients with retinal detachment. Apr 2022 [internet publication]. https://clinicaltrials.gov/ct2/show/NCT02834559?term=NCT02834559&draw=2&rank=1